Research
What the documents actually say.
Two things get written here. One is an investigation, run over the seller record this site maintains, into a question the market would rather leave vague. The other is a close reading of the trial literature on a specific drug or risk. Neither is a news summary, and neither goes out with a number we could not trace to the document it came from.
Research formats
Related tools
- Data investigation6 min · 3 sources
Tesamorelin for Weight Loss? Read Its Own Label
Tesamorelin is a real approved drug with a current FDA label, which is exactly why sellers reach for it. But approved and approved FOR THIS are different claims, and the gap is where the marketing lives. Its prescribing information states the indication — excess abdominal fat in HIV-infected adults with lipodystrophy — and then states, under Limitations of Use, that it is not indicated for weight loss management.
Read the analysis→ - Scientific deep-dive6 min · 3 sources
Is Zepbound a Semaglutide? Brand Names vs Molecules
Wegovy and Ozempic are both semaglutide. Zepbound and Mounjaro are both tirzepatide. Each manufacturer took one molecule and gave it two names, one for the diabetes label and one for the weight label — same substance, different box, often a very different price. Almost every confusing thing in this market traces back to that gap, including why a compounded seller can quote a trial result from a product they are not selling.
Read the analysis→ - Data investigation7 min · 4 sources
Sermorelin for Weight Loss: Zero Trials, Real History
Sermorelin has a stranger history than most of this market. It was FDA-approved as Geref for diagnosing and treating growth hormone deficiency in children, and FDA formally recorded that its withdrawal was NOT for safety or effectiveness reasons — which puts compounded sermorelin on firmer ground than most peptides sold online. What it has never had is a single published trial for weight loss, the use 125 of the 556 sellers in this register offer it for.
Read the analysis→ - Data investigation7 min · 5 sources
CJC-1295 and Ipamorelin: What FDA Recorded
The two are sold together on the theory that one sustains the growth hormone pulse the other triggers, and that pharmacology is real. What is missing is the second step. The human trials measured hormone levels — and the most rigorous one tested ipamorelin for postoperative ileus, a bowel-motility problem after surgery. FDA meanwhile named two specific cardiovascular effects for CJC-1295, language it did not use for other peptides in this market.
Read the analysis→ - Data investigation6 min · 3 sources
Medicare and GLP-1s: the $50 Bridge That Opened in July
The answer to “does Medicare cover Wegovy” changed on 1 July 2026, and most pages answering it are describing the old rules. The Medicare GLP-1 Bridge is a short-term CMS demonstration running to 31 December 2027 — $50 a month, prior authorization required, and deliberately outside the Part D benefit, because the statute barring Medicare from covering weight-loss drugs has not changed. The eligibility test is applied to when you STARTED therapy, not to today’s numbers, and only the Zepbound KwikPen is covered.
Read the analysis→ - Data investigation7 min · 3 sources
GLP-1 Prior Authorization: the Criteria, the Clock, the Appeal
A denial is written to sound final. It is not: the process runs on deadlines set in federal law rather than by your insurer, and the two that belong to you — 180 days to appeal, 4 months to escalate — are the two people miss. External review is the step almost nobody reaches, where a body outside the company decides and the insurer must comply with the outcome. You can appoint your own doctor to file it for you.
Read the analysis→ - Scientific deep-dive9 min · 4 sources
Foundayo (Orforglipron): the First GLP-1 Pill for Weight
Foundayo does something no injection can: once a day, with or without food, no needle at any point. It is a non-peptide small molecule, which is why it needs none of the fasting ritual oral semaglutide demands. At the maximum dose it produced 11.1% weight loss over 72 weeks against 2.1% on placebo — a real result, and below semaglutide’s 14.9% and tirzepatide’s 20.9%. Being a small molecule also brings CYP3A4 interactions the injectables do not have, including advice to switch off oral contraceptives.
Read the analysis→ - Scientific deep-dive8 min · 4 sources
Drinking on a GLP-1: What the Label Actually Says
The label says nothing about drinking: eleven uses of the word “alcohol”, every one either a liver-disease name or an alcohol swab in the injection steps. That is not permission and not a prohibition, so the honest answer has to come from the pharmacology and from the trials. Those trials are the surprise — semaglutide cut craving and heavy drinking days in randomized tests. But the placebo arm of the larger one fell 26.4 points on therapy alone, and the drug’s own contribution was 13.7.
Read the analysis→ - Scientific deep-dive11 min · 10 sources
GLP-1s, Pregnancy and Trying to Conceive: What the Labels Say
All three semaglutide labels name at least two months ahead of a planned pregnancy and tie it to a half-life of about a week; neither tirzepatide label states any interval at all. The animal data sit behind every one of the cautions, the human data are limited, and the two largest 2026 analyses call their own estimates imprecise. No dose, no schedule, no instruction to stop.
Read the analysis→ - Scientific deep-dive9 min · 8 sources
GLP-1s and Hormonal Birth Control: Which Labels Carry the Warning
Mounjaro and Zepbound tell prescribers to move a patient off a swallowed hormonal method, or add a barrier one, for four weeks from the first dose and four weeks after each increase. Ozempic, Wegovy and the oral tablets say nothing of the kind. The mechanism is delayed stomach emptying, which is also why anything not swallowed sits outside the advisory.
Read the analysis→ - Scientific deep-dive11 min · 12 sources
What Happens When You Stop a GLP-1: What the Withdrawal Trials Measured
This is one of the few questions about GLP-1 drugs with a direct randomized answer, because STEP 4, the STEP 1 extension and SURMOUNT-4 were built to test it. Weight returned in all three, and the post hoc work shows the metabolic reversal tracking how much weight came back rather than the act of stopping. The article gives no dosing advice, no taper and no recommendation either way — nearly half the people who stop in practice do so over cost, which is a conversation for a prescriber, not a website.
Read the analysis→ - Data investigation11 min · 12 sources
Semaglutide Cost Without Insurance: The Routes, and What Sets the Number
This article names no figure, on purpose: cash pricing for semaglutide has been rewritten repeatedly this year by the manufacturers and by the federal government, so a number written into a sentence is wrong within weeks. What holds still is the set of routes — manufacturer-direct self-pay, the federal price channel, and the narrow compounded route that survived — and the four variables that set the arithmetic on each. The last of those is the one people skip: a plan that refuses weight management may already cover the same molecule under its diabetes label.
Read the analysis→ - Data investigation8 min · 3 sources
How Many Units Is Your GLP-1 Dose? It Depends on the Vial
Twenty units of a 2.5 mg/mL semaglutide vial is 0.5 mg. Twenty units of a 5 mg/mL vial is 1 mg — the same mark on the same syringe, twice the drug. FDA has documented patients receiving five to twenty times their intended dose from exactly this confusion, some requiring hospitalization. Here is the arithmetic, both conversion tables for every concentration in common US compounding use, and the one line you have to read off your own vial first.
Read the analysis→ - Data investigation7 min · 3 sources
Is Microdosing Actually Cheaper? We Checked All 556 Sellers
Microdosing is sold as the cheap way into a GLP-1. Across the 26 same-drug comparisons in our register it is cheaper in 23, at a median of about two-thirds the standard price. The catch is that the microdose is quoted month-to-month while the standard dose is quoted “as low as” a twelve-month prepay, so the headline gap is not the gap you get. Including the four comparisons we got wrong first, and why.
Read the analysis→ - Scientific deep-dive7 min · 4 sources
Do GLP-1 Patches Work? The Molecule Is Too Big
“GLP-1 patch” is one of the most searched terms in this market and there is no product behind it. The reason is not a missing trial — it is molecular weight. Skin’s working ceiling is about 500 daltons; semaglutide is 4,114. Here is the arithmetic, what is actually in the patches being sold, why microneedle research does not apply to them, and how to run the same check on the next product advertised to you.
Read the analysis→ - Data investigation8 min · 3 sources
How to Get a GLP-1 Covered by Insurance
First, whether your plan covers weight-management drugs at all. Second, whether you meet its criteria. Third, whether a denial is worth appealing — and sometimes it is not, because an exclusion has nothing for an appeal to overturn. This is the mechanism in the order it runs, the questions that get a straight answer at each stage, and the diagnosis that changes the conversation entirely.
Read the analysis→ - Data investigation8 min · 3 sources
The Cheapest Way to Get a GLP-1 Without Insurance
Paying cash changes the question from what your plan will approve to what the market charges, and the market charges an enormous range for the same drug. Across the sellers in this register compounded semaglutide runs from about $79 a month to $299 at the ninetieth percentile, median near $190. This is what the tiers are, what makes the cheap end cheap, and the four questions that decide whether the number you are quoted is the number you will pay.
Read the analysis→ - Scientific deep-dive6 min · 3 sources
Where to Inject a GLP-1, and Why Rotation Matters
Three sites, and only three: the abdomen at least two inches from the navel, the front of the thigh, and the back of the upper arm. Every approved GLP-1 directs the same three. What most pages leave out is what happens when you reuse one — the tissue scars, absorption turns erratic, and the resulting plateau gets misread as the drug losing effect, at exactly the moment a seller offers a higher dose or a pricier tier.
Read the analysis→ - Scientific deep-dive8 min · 4 sources
Retatrutide: What the Evidence Actually Shows
Retatrutide is Eli Lilly’s investigational triple agonist and the biggest search term in this market for a drug nobody can lawfully buy. Two weight-loss figures circulate: 24.2% at 48 weeks from a peer-reviewed phase 2 trial in 81 people, and 28.7% at 68 weeks from a topline press release that has not been published or reviewed. Plus the number sellers never quote — dysesthesia in 20.9% of the top-dose arm against 0.7% on placebo.
Read the analysis→ - Data investigation7 min · 3 sources
BPC-157: What FDA Actually Said About It
BPC-157 is sold everywhere and approved nowhere. FDA evaluated it for the 503A compounding list, wrote down why it was concerned, and the nomination was withdrawn before it was added — which leaves it outside the compounding system entirely. The regulator’s actual finding is not that the peptide is dangerous but that nobody has established whether it is safe, which for an injectable is the worse position of the two.
Read the analysis→ - Data investigation9 min · 8 sources
What Is in a Compounded GLP-1 Vial: How to Read the Label
Concentration is not dose, and a unit on an insulin syringe is a volume rather than a milligram amount — which is why FDA has reports of patients administering five to twenty times what was intended. What mg/mL means, why two pharmacies' vials need different volumes for the same prescription, what beyond-use dating is, and what an added ingredient like B12 changes about the contents.
Read the analysis→ - Data investigation10 min · 9 sources
How to Verify an Online GLP-1 Pharmacy: Six Public Checks
Most GLP-1 sold online arrives through three parties wearing one brand, and only one of them holds a license anyone can look up. This is the procedure we use ourselves — state board lookup, FDA's outsourcing facility register, accreditation directories and the warning letter database — plus the FDA categories that sellers invoke and that do not exist.
Read the analysis→ - Data investigation9 min · 7 sources
How Much Does Compounded Semaglutide Cost? What Drives the Number
We do not print a price in this article, and that is the point: seller figures move weekly and belong on a page that carries a date. What does not move is the structure of the bill — seven ways an advertised number is not the standing one, three things that legitimately differ between sellers, and the questions that surface both before you pay.
Read the analysis→ - Scientific deep-dive9 min · 6 sources
Compounded Semaglutide vs Ozempic and Wegovy: What Is Actually Different
The molecule can be identical. The product is not: salt forms are different active ingredients, a compounded vial is a concentration rather than a metered dose, and no compounded preparation carries a label FDA reviewed. It also settles the question underneath the query — Ozempic and Wegovy are one molecule with two approved labels.
Read the analysis→
How we work
A figure in an investigation was read off the seller’s own page on a recorded date. A clinical statement traces to PubMed, an FDA document, or the trial paper itself, and never to a press release, a listicle or another comparison site. Where two sources disagree we say so on the page instead of picking the tidier one. An article gets revisited when the evidence under it moves, though we will not pretend that happens the instant a study lands.
Nothing here is a recommendation to take a particular drug, and none of it can weigh your history the way a clinician can. Take the decision to one. How we rate sellers →